Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 314

3 896 clinical trials
1 542 recruiting
703 conditions
31 countries

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 896 trials across Europe, recruiting first

Click a country to filter the trials

Quick filters

3 896 clinical trials

Study on Langerhans Cell Histiocytosis Treatment in Children and Adolescents Using Cladribine, Prednisolone, and Cytarabine

Not recruiting

Registered drugNo placebo

Study on Langerhans Cell Histiocytosis Treatment in Children and Adolescents Using Cladribine, Prednisolone, and Cytarabine

Registered drugNo placebo

Austria

Participants:0–17 years
Substances:Alemtuzumab
Sponsor:St. Anna Childrens Cancer Research Institute GmbH

Contact Research Centre

Pancreatic carcinoma

Not recruiting

Registered drugNo placebo

Study comparing FOLFIRINOX versus gemcitabine-based chemoradiotherapy in patients with resectable or borderline resectable pancreatic cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Contact Research Centre

Plasma cell myeloma

Not recruiting

Registered drugNo placebo

Study on Isatuximab, Bortezomib, and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Registered drugNo placebo

Denmark

Participants:65+ years
Substances:Bortezomib
Sponsor:Oslo University Hospital HF

Contact Research Centre

Waldenstrom's macroglobulinaemia

Not recruiting

Registered drugNo placebo

Study on Carfilzomib and Ibrutinib for Patients with Waldenström’s Macroglobulinemia

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Carfilzomib
Sponsor:Universitaetsklinikum Ulm AöR

Contact Research Centre

Acute myeloid leukaemia+1

Not recruiting

Registered drugNo placebo

Study on Midostaurin and Decitabine for Adults with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Who Are Unfit for Intensive Treatment

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Decitabine
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Small cell lung cancer recurrent

Not recruiting

Registered drugNo placebo

Study of Tarlatamab Treatment for Patients with Small Cell Lung Cancer Who Have Not Responded to Two or More Previous Treatments

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Siltuximab
Sponsor:Amgen Inc.

Contact Research Centre

Lung neoplasm malignant

Not recruiting

Registered drugNo placebo

Study of Atezolizumab and Dendritic Cell Vaccine for Maintenance Treatment in Patients with Extensive Stage Small Cell Lung Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Instituto Oncologico Dr. Rosell S.L.

Contact Research Centre

Acute myeloid leukaemia+2

Not recruiting

Registered drugNo placebo

Study Comparing Pevonedistat, Venetoclax, and Azacitidine with Venetoclax and Azacitidine in Adults with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study on the Effect of Tamoxifen and Chemotherapy in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer with Low Recurrence Scores

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer De Mama

Contact Research Centre

Hormone receptor positive breast cancer

Not recruiting

Registered drugNo placebo

Study Comparing Standard Chemotherapy with Letrozole and Abemaciclib for High/Intermediate Risk HR-Positive, HER2-Negative Breast Cancer Patients

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer De Mama

Contact Research Centre

Colorectal cancer metastatic

Not recruiting

Registered drugNo placebo

Study of FOLFOX6m, Bevacizumab, and Irinotecan for Patients with Colorectal Cancer and Liver Metastases

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Grupo Espanol Multidisciplinar En Cancer Digestivo

Contact Research Centre

Anal squamous cell carcinoma+5

Not recruiting

Registered drugNo placebo

Study on Pelareorep and Atezolizumab for Patients with Advanced or Metastatic Gastrointestinal Cancers

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Oncolytics Biotech Inc.

Contact Research Centre

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab460 clinical trials Carboplatin339 clinical trials Cisplatin284 clinical trials Paclitaxel263 clinical trials Fluorouracil237 clinical trials Oxaliplatin227 clinical trials Nivolumab216 clinical trials Dexamethasone169 clinical trials Bevacizumab163 clinical trials

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 314

Conditions in this area

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 896 clinical trials

Study on Langerhans Cell Histiocytosis Treatment in Children and Adolescents Using Cladribine, Prednisolone, and Cytarabine

Study on Langerhans Cell Histiocytosis Treatment in Children and Adolescents Using Cladribine, Prednisolone, and Cytarabine

Pancreatic carcinoma

Study comparing FOLFIRINOX versus gemcitabine-based chemoradiotherapy in patients with resectable or borderline resectable pancreatic cancer

Plasma cell myeloma

Study on Isatuximab, Bortezomib, and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Waldenstrom's macroglobulinaemia

Study on Carfilzomib and Ibrutinib for Patients with Waldenström’s Macroglobulinemia

Acute myeloid leukaemia+1

Study on Midostaurin and Decitabine for Adults with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Who Are Unfit for Intensive Treatment

Small cell lung cancer recurrent

Study of Tarlatamab Treatment for Patients with Small Cell Lung Cancer Who Have Not Responded to Two or More Previous Treatments

Lung neoplasm malignant

Study of Atezolizumab and Dendritic Cell Vaccine for Maintenance Treatment in Patients with Extensive Stage Small Cell Lung Cancer

Acute myeloid leukaemia+2

Study Comparing Pevonedistat, Venetoclax, and Azacitidine with Venetoclax and Azacitidine in Adults with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy

Hormone receptor positive HER2 negative breast cancer

Study on the Effect of Tamoxifen and Chemotherapy in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer with Low Recurrence Scores

Hormone receptor positive breast cancer

Study Comparing Standard Chemotherapy with Letrozole and Abemaciclib for High/Intermediate Risk HR-Positive, HER2-Negative Breast Cancer Patients

Colorectal cancer metastatic

Study of FOLFOX6m, Bevacizumab, and Irinotecan for Patients with Colorectal Cancer and Liver Metastases

Anal squamous cell carcinoma+5

Study on Pelareorep and Atezolizumab for Patients with Advanced or Metastatic Gastrointestinal Cancers

Filter the trials

Substances studied in this area

Prefer not to search? Our Concierge searches the trials for you.